(Q38239854)

31 August 2017

Antibody-drug conjugates: an emerging modality for the treatment of cancer (English)

1 reference

31 August 2017

1 reference

Mauricio Leal

1

1 reference

31 August 2017

Puja Sapra

2

1 reference

31 August 2017

Sara A Hurvitz

3

1 reference

31 August 2017

Peter Senter

4

1 reference

31 August 2017

Alan Wahl

5

1 reference

31 August 2017

Melissa Schutten

6

1 reference

31 August 2017

Dhaval K Shah

7

1 reference

31 August 2017

Nahor Haddish-Berhane

8

1 reference

31 August 2017

Omar Kabbarah

9

1 reference

31 August 2017

language of work or name

English

0 references

publication date

1 August 2014

1 reference

Annals of the New York Academy of Sciences

31 August 2017

1 reference

31 August 2017

1321

1 reference

31 August 2017

41-54

1 reference

Antibody-drug conjugate (ADC) clinical pipeline: a review

31 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Pharmacokinetics and ADME characterizations of antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Antibody conjugate therapeutics: challenges and potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Antibody-drug conjugates in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Identification of stem cells in small intestine and colon by marker gene Lgr5

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

STEAP proteins: from structure to applications in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Tissue distribution studies of protein therapeutics using molecular probes: molecular imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Antibody-drug conjugate payloads

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

A general approach to site-specific antibody drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Site-specific antibody drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

Trends in translational medicine and drug targeting and delivery: new insights on an old concept-targeted drug delivery with antibody-drug conjugates for cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12499

21 January 2018

Identifiers

DOI

10.1111/NYAS.12499

1 reference

31 August 2017

1 reference